GERMANTOWN, Md., June 22 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it has entered into an agreement with Innovex, the commercialization division of Quintiles Transnational Corp., to provide contract sales and marketing services to Advancis. Terms of the agreement include the hiring, training and deployment of 75 sales representatives dedicated to the sales and promotion of Advancis' recently approved 333mg and 750mg strengths of its cephalosporin antibiotic, Keflex(R) Capsules (Cephalexin, USP). Advancis expects to begin promotion to healthcare professionals on July 17, 2006.
Under the agreement, Innovex will provide contract sales, marketing, and commercialization services, including sales representative recruitment, sales force automation and sample accountability services, promotional education programs and other related commercialization services. The term of the agreement is two years. All 75 sales representatives have been identified, hired, and will be on-board shortly.
"We are very pleased to have Innovex as a key Advancis partner and to have their significant experience and sales expertise dedicated to the launch and commercial success of our new Keflex strengths," said Edward M. Rudnic, Ph.D., president and CEO of Advancis. "Innovex's demonstrated capabilities and expertise in building successful sales teams and promoting antibiotic products provide an outstanding foundation for our first product launch. In addition, we look forward to building our relationship with Innovex as we launch and grow our commercial efforts over the coming years."
Innovex specializes in providing contract sales, marketing and commercialization support services to the pharmaceutical, healthcare, and biotechnology industries. Innovex has deployed more than 150 sales and health management services teams and launched more than 160 products. Additionally, Innovex has deployed over 1,600 sales representatives to promote anti- infective products.
The new Keflex (cephalexin) 750mg strength provides healthcare professionals a more convenient way to deliver a total daily dose of 1500mg per day, by providing them an option to prescribe just two daily doses of the 750mg capsules. Keflex is approved for adult dosages ranging from one to four grams per day in divided doses; however, the majority of prescriptions are currently written for cephalexin 500mg three times daily -- totaling 1500mg per day.
"We're looking forward to working with Advancis on this project as they move forward in establishing their presence in the marketplace," said Tony Yost, President of Innovex US. "The anti-infective market is highly competitive and presents an ideal opportunity for the high performing representatives that we will attract and develop on behalf of the Advancis team."
Advancis acquired the rights to manufacture, market, and sell Keflex in the United States in July of 2004. Cephalexin is the third most prescribed outpatient antibiotic in the United States, with more than 25 million prescriptions written annually. Keflex is the number-one most prescribed oral cephalosporin antibiotic and is also the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.
Innovex, a unit of Quintiles, is the world's leading commercial solutions provider and offers sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. Since 1996, Innovex has created more than 150 contract sales forces and Health Management Services teams with more than 16,000 representatives who have launched more than 160 products. For more information, visit http://www.innovex.com.
Quintiles is the global leader in pharmaceutical services. We improve healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in 50 countries. For more information, visit the company's Web site at http://www.quintiles.com.
About Advancis Pharmaceutical:
Advancis Pharmaceutical Corp. is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com.
Keflex(R) Capsules (Cephalexin, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. Keflex is currently available in 250mg capsules, 500mg capsules, and powder for oral suspension. Keflex is contraindicated in patients with known allergy to the cephalosporin group of antibiotics. Before therapy with cephalexin is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalexin, cephalosporins, penicillins, or other drugs. Keflex should be administered with caution in the presence of markedly impaired renal function or a history of gastrointestinal disease, particularly colitis. More information on Keflex and prescribing information are available at http://www.advancispharm.com/products/keflex.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are based on Advancis' current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking.
The actual results realized by Advancis could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) reach profitability, (2) prove that the preliminary findings for its product candidates are valid, (3) receive required regulatory approvals, (4) successfully conduct clinical trials in a timely manner with favorable results, (5) establish its competitive position for its products, (6) develop and commercialize products that are superior to existing or newly developed competitor products, (7) develop products without any defects, (8) have sufficient capital resources to fund its operations, (9) protect its intellectual property rights and patents, (10) implement its sales and marketing strategy and reach its sales goals, (11) successfully attract and retain collaborative partners and have its partners fulfill their obligations, (12) successfully sell and market its products, and (13) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Advancis undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Advancis Pharmaceutical Corporation